Tonmya is under clinical development by Tonix Pharmaceuticals Holding and currently in Phase III for Fibromyalgia (Fibromyalgia Syndrome). According to GlobalData, Phase III drugs for Fibromyalgia (Fibromyalgia Syndrome) have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Tonmya’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tonmya overview
TNX-102 SL (cyclobenzaprine hydrochloride, Tonmya) is under development for the treatment of fibromyalgia, Long COVID Syndrome (Long COVID) also known as Post-Acute Sequelae of COVID-19 (PASC), agitation in Alzheimer’s disease, acute stress disorder, post-traumatic stress disorder (PTSD) and alcohol use disorder. The the drug candidate is administered through sublingual route as tablet. It acts by targeting serotonin receptor type 2a (5HT2a), alpha-1 adrenergic receptor and histamine H1 receptor and muscarinic receptor (M1). The drug candidate is developed based on technology that involves a mixture of cyclobenzaprine and lipids. It was also under development for post-traumatic stress disorder (PTSD).
Tonix Pharmaceuticals Holding overview
Tonix Pharmaceuticals Holding (Tonix) a developer of pharmaceutical products to address public health challenges. The company offers pharmaceutical products and treatments for disorders of the central nervous system including fibromyalgia, post-traumatic stress disorder and episodic tension-type headache. Its products include Central Nervous System Portfolio; TNX-102 SL, TNX-1300, TNX-1900, Immunology Portfolio; TNX-1500(Organ Transplant Rejection / Autoimmune Disorders), TNX-1850 COVID-19 Vaccine and Rare Disease Portfolio; TNX-2900 (Prader-Willi Syndrome). Its disintegrating sublingual tablets contain a dose and formulation of cyclobenzaprine and are used for the treatment of fibromyalgia and post-traumatic stress disorder. It markets its products through a network of distributors across the US. It has operations in Ireland, Canada and the US. Tonix is headquartered in New York, the US
For a complete picture of Tonmya’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
